Skip to main content
. Author manuscript; available in PMC: 2018 Apr 20.
Published in final edited form as: Lancet Neurol. 2015 Apr;14(4):388–405. doi: 10.1016/S1474-4422(15)70016-5

Table 1. Selected clinicals trials to date.

Drug Treatment Outcome Patients
Rogers et al, 1993207 Indomethacin 6 months Positive effects after marked attrition 41 AD
De Jong et al, 2008208 Indomethacin 1 year Neutral to positive effects after marked attrition 51 mild to moderate AD
Aisen et al, 2000211 Prednisone 1 year Neutral to negative effects 138 AD
Aisen et al, 2003209 Naproxen, rofecoxib 1 year Neutral to negative effects 351 mild-to-moderate AD
Aisen et al, 2002228 Nimesulide 3 months Neutral effects 40 AD
Reines et al, 2004210 Rofecoxib 1 year Neutral to negative effects 692 mild-to-moderate AD
Thal et al, 2005229 Rofecoxib 3.5 years, preventive Neutral to negative effects on conversion to AD 1457 mild cognitive impairment
Van Gool et al, 2001212 Hydroxychloro quine 18 months Neutral effects 168 mild AD
ADAPT Research Celecoxib 2 years, preventive Neutral to negative effects 2528 normal with family
Research Group, 2007, 2008218,230 effects with family history of AD
ADAPT Research Group, 2007, 2008218,230 Naproxen 2 years, preventive Neutral to negative effects 2528 normal wit family history of AD
Simons et al, 2002213 Simvastatin 26 weeks No effects on CSF Aβ 44 AD
Sparks et al, 2005214 Atorvastin 72 weeks Neutral effects 640 mild to moderate AD
Feldman et al, 2010215 Atorvastatin 1 year Neutral to positive effects 67 mild AD
Gold et al, 2007217 Rosiglitazone 24 weeks Neutral effects 693 mild to moderate AD
Breitner et al, 2011219 Naproxen 4 years, preventive Neutral to positive effects 2528 normal with family history of AD
Breitner et al, 2011219 Celecoxib 4 years, preventive neutral to negative effects 2528 normal with family history of AD

We searched PubMed for randomised controlled trials published in English. The table provides a list of trial results that have had a notable influence on the field, in our view, and is not an exhaustive list of studies. Priority was given to trials with sufficient numbers of participants, definition of clinical outcomes, and specification of design methodology to allow firm conclusions to be drawn (including inference of uncertainty). Two older trials were included because of their influence on later work, despite the fact that they failed to meet the foregoing criteria.